PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16366-16378

  Huang, Li ^a   Peng, Yang ^a   Zhong, Guangzheng ^a   Xie, Weibin ^a   Dong, Wen ^a   Wang, Bo ^a   Chen, Xu ^a   Gu, Peng ^a   He, Wang ^a   Wu, Shaoxu ^a   Lin, Tianxin ^a   Huang, Jian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bladder cancer; Cell cycle; Cyclin B1; PBRM1

Indexed keywords

CYCLIN B1; CCNB1 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PBRM1 GENE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLADDER TUMOR; CARCINOGENESIS; CELL MOTION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANIMALS; BASE SEQUENCE; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN B1; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84937851546     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3879     Document Type: Article

References (38)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63:11-30.
2. Al Hussain TO and Akhtar M. Molecular basis of urinary bladder cancer. Advances in anatomic pathology. 2013; 20:53-60.
3. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M and European Association of U. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. European urology. 2013; 64:639-653.
4. Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Ferno M, Ringner M, Mansson W, Liedberg F, Lindgren D, et al. A molecular taxonomy for urothelial carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:3377-3386.
5. Sjodahl G, Lauss M, Gudjonsson S, Liedberg F, Hallden C, Chebil G, Mansson W, Hoglund M and Lindgren D. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PloS one. 2011; 6:e18583.
6. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, Gudjonsson S, Liedberg F, Patschan O, Mansson W, Ferno M and Hoglund M. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PloS one. 2012; 7:e38863.
7. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, Veerla S, Ryden T, Mansson W, Liedberg F and Hoglund M. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer research. 2010; 70:3463-3472.
8. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Jr., Vogelstein B, Kinzler KW, Velculescu VE and Papadopoulos N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330:228-231.
9. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Zhou S, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature genetics. 2011; 43:828-829.
10. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011; 469:539-542.
11. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature genetics. 2011; 43:1219-1223.
12. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A and Pollack JR. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:E252-259.
13. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. The New England journal of medicine. 2010; 363:1532-1543.
14. Shain AH and Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PloS one. 2013; 8:e55119.
15. Timp W and Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nature reviews Cancer. 2013; 13:497-510.
16. Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, Memeo L, Hibshoosh H and Parsons R. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer research. 2008; 68:1667-1674.
17. Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, Uslu IN and Tansug Z. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncology letters. 2014; 8:25-32.
18. Burrows AE, Smogorzewska A and Elledge SJ. Polybromoassociated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:14280-14285.
19. da Costa WH, Rezende M, Carneiro FC, Rocha RM, da Cunha IW, Carraro DM, Guimaraes GC and de Cassio Zequi S. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU international. 2014; 113:E157-163.
20. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature genetics. 2011; 43:875-878.
21. Kaufman DS, Shipley WU and Feldman AS. Bladder cancer. Lancet. 2009; 374(9685):239-249.
22. Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672-1677.
23. Malumbres M and Barbacid M. Mammalian cyclindependent kinases. Trends in biochemical sciences. 2005; 30:630-641.
24. Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S and Yamada T. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:2518-2528.
25. Nimeus-Malmstrom E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L, Amini RM, Jirstrom K, Warnberg F, Blomqvist C, Ferno M and Fjallskog ML. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. International journal of cancer Journal international du cancer. 2010; 127:961-967.
26. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH and Kalinichenko VV. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer research. 2006; 66:2153-2161.
27. Kawamoto H, Koizumi H and Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. The American journal of pathology. 1997; 150:15-23.
28. Wang A, Yoshimi N, Ino N, Tanaka T and Mori H. Overexpression of cyclin B1 in human colorectal cancers. Journal of cancer research and clinical oncology. 1997; 123:124-127.
29. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ and Dutta A. Expression of cell cycle-regulated proteins in prostate cancer. Cancer research. 1996; 56:4159-4163.
30. Kushner J, Bradley G, Young B and Jordan RC. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 1999; 28:77-81.
31. Murakami H, Furihata M, Ohtsuki Y and Ogoshi S. Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Archiv: an international journal of pathology. 1999; 434:153-158.
32. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK and Mao L. Overexpression of cyclin B1 in early-stage nonsmall cell lung cancer and its clinical implication. Cancer research. 2000; 60:4000-4004.
33. Ohshima K, Haraoka S, Fujiki T, Yoshioka S, Suzumiya J, Kanda M and Kikuchi M. Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression. Pathology international. 1999; 49:506-512.
34. Banerjee SK, Weston AP, Zoubine MN, Campbell DR and Cherian R. Expression of cdc2 and cyclin B1 in Helicobacter pylori-associated gastric MALT and MALT lymphoma: relationship to cell death, proliferation, and transformation. The American journal of pathology. 2000; 156:217-225.
35. Kim SK, Roh YG, Park K, Kang TH, Kim WJ, Lee JS, Leem SH and Chu IS. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:3233-3243.
36. Innocente SA, Abrahamson JL, Cogswell JP and Lee JM. p53 regulates a G2 checkpoint through cyclin B1. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:2147-2152.
37. Shen M, Feng Y, Gao C, Tao D, Hu J, Reed E, Li QQ and Gong J. Detection of cyclin b1 expression in g(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer research. 2004; 64:1607-1610.
38. Aaltonen K, Amini RM, Heikkila P, Aittomaki K, Tamminen A, Nevanlinna H and Blomqvist C. High cyclin B1 expression is associated with poor survival in breast cancer. British journal of cancer. 2009; 100:1055-1060.